Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer
HPV and Gynecologic Cancer
Related content
HPV and Gynecologic Cancer
Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer
Gynecol Oncol.
Torres D, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Wang C, Langstraat CL, Cliby WA
doi: 10.1016/j.ygyno.2018.11.019.
HPV and Gynecologic Cancer
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed?
Am J Obstet Gynecol.
Klein DA, Mann AK, Freeman AH, Liao CI, Kapp DS, Chan JK
doi: 10.1016/j.ajog.2019.07.050.
HPV and Gynecologic Cancer
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer
Am J Obstet Gynecol.
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA
doi: 10.1016/j.ajog.
HPV and Gynecologic Cancer
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
N Engl J Med.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS
doi: 10.1056/NEJMoa1708618.
HPV and Gynecologic Cancer
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Lancet Oncol
Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA
doi: 10.1016/S1470-2045(21)00342-9
Pregnancy and ChildbirthReproductive Health
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data
J Clin Oncol.
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L
doi: 10.1200/JCO.2018.78.0858.
HPV and Gynecologic Cancer
The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review
Gynecol Oncol.
Timmermans M, van der Hel O, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RF
doi: 10.1016/j.ygyno.2019.02.019.
Uro-Oncology
No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study
World J Urol.
Jerlström T, Chen R, Liedberg F, Andrén O, Ströck V, Aljabery FAS, Hosseini A, Sherif A, Malmström PU, Ullén A, Gårdmark T, Fall K
doi: 10.1007/s00345-019-02770-2
COMMENTED
HPV and Gynecologic Cancer
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 3
Recommended by
Prof. Dr Andreas Lohri, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
N Engl J Med.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS
doi: 10.1056/NEJMoa1902626.